CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 190 enrolled
Drug / intervention
Corsano CardioWatch 287-2device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05899959
NCT05899959N/ACompleted

Remote Cardiac Monitoring by the Corsano CardioWatch 287-2 Evaluation Study

Corsano Health B.V.·observational·Posted Jun 12, 2023·Updated Aug 26, 2024

In Brief

An observational study evaluating Corsano CardioWatch 287-2 for Atrial Fibrillation and 4 related conditions. Completed, enrolled 190 participants across 1 site.

Detailed Summary

In this study, a wristband that monitors hearth rhythm and blood pressure is assessed in free living conditions. Two groups of patients are being recruited: patients receiving an EKG holter and patients receiving an automatic blood pressure monitor. Patients wear the wristband for 28 days. During this time, the number of atrial fibrillation episodes detected by the wristband is being counted, which is to be compared with the number of episodes detected by the holter. Also, blood pressure is measured continuously, which is to be compared with daily blood pressure measurements using a conventional blood pressure cuff.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJun 12, 2023
Enrollment StartJun 15, 2023
Primary CompletionDec 28, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.1 years ago

Interventions

Corsano CardioWatch 287-2device

Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.